
Athersys ATHX
Quarterly report 2023-Q3
added 11-16-2023
Athersys General and Administrative Expenses 2011-2026 | ATHX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 M | 15.9 M | 11.4 M | 10.4 M | 8.47 M | 7.84 M | 7.54 M | 6.91 M | 6.06 M | 4.75 M | 4.92 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 M | 4.75 M | 9.48 M |
Quarterly General and Administrative Expenses Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.81 M | 2.34 M | 2.82 M | - | 3.74 M | 5.16 M | 4.1 M | - | 3.63 M | 4.16 M | 8.84 M | - | 3.7 M | 4.43 M | 3.47 M | - | 2.96 M | 2.87 M | 3.11 M | - | 2.56 M | 2.38 M | 2.66 M | - | 2.11 M | 2.21 M | 2.07 M | - | 1.83 M | 1.98 M | 2.01 M | - | 1.94 M | 1.92 M | 1.89 M | - | 1.7 M | 1.83 M | 1.78 M | - | 1.45 M | 1.56 M | 1.51 M | - | 1.08 M | 1.16 M | 1.26 M | - | 1.11 M | 1.39 M | 1.22 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.84 M | 1.08 M | 2.58 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
91.6 M | $ 15.94 | -3.66 % | $ 3.8 B | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 3.51 | -3.31 % | $ 1.05 B | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.84 | 1.57 % | $ 4.58 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.16 | 1.51 % | $ 2.54 B | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
250 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.49 | -8.59 % | $ 380 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
60.8 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
63.3 M | $ 162.3 | -1.08 % | $ 8.07 B | ||
|
BridgeBio Pharma
BBIO
|
531 M | $ 65.02 | -2.29 % | $ 12.5 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
7.04 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
4.31 M | $ 2.77 | -1.42 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 60.51 | 0.13 % | $ 11.6 B | ||
|
Equillium
EQ
|
13.6 M | $ 1.75 | - | $ 60.8 M | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 8.27 | -1.19 % | $ 1.36 B | ||
|
Cabaletta Bio
CABA
|
19.2 M | $ 3.21 | -6.52 % | $ 3.75 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
78.7 M | $ 3.01 | -5.94 % | $ 1.08 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
12.8 M | $ 25.27 | -0.9 % | $ 677 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
449 M | $ 34.25 | -4.03 % | $ 3.56 B |